【24h】

Allogeneic stem cell transplantation for severe aplastic anemia: Graft rejection remains a problem.

机译:异基因干细胞移植治疗严重再生障碍性贫血:移植排斥仍然是一个问题。

获取原文
获取原文并翻译 | 示例
           

摘要

We reviewed the outcome in 15 consecutive patients with severe aplastic anemia with a median age of 23 years who received matched sibling peripheral blood stem cell transplantation. Conditioning regimen was cyclophosphamide (Cy)+anti-thymocyte globulin (ATG). Cumulative incidence of transplant related mortality, graft failure, acute and chronic GVHD were 20%, 33%, 25%, and 8.3%, respectively. Conditioning with Cy only, resulted in higher rejection rate compared to Cy plus ATG (75% versus 12.5%, p=0.03). Eighty percent of patients are alive with a median follow-up of 19.5 (4.6-35.6) months. Two of the three patients who were re-transplanted with fludarabine had sustained donor chimerism.
机译:我们回顾了中位年龄为23岁的连续15例严重再生障碍性贫血患者的结局,这些患者接受了同级兄弟外周血干细胞移植。调理方案为环磷酰胺(Cy)+抗胸腺细胞球蛋白(ATG)。移植相关死亡率,移植失败,急性和慢性GVHD的累积发生率分别为20%,33%,25%和8.3%。与Cy加ATG相比,仅使用Cy进行调理会导致更高的排斥率(75%对12.5%,p = 0.03)。 80%的患者还活着,中位随访时间为19.5(4.6-35.6)个月。氟达拉滨再移植的三例患者中有两例持续供体嵌合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号